Merit Medical Launches basixSKY™ Inflation Device
Merit Medical Systems (NASDAQ: MMSI) has announced the US launch of the basixSKY Inflation Device, expanding its portfolio of inflation devices. The device, designed for ease of use and efficiency, is available as a standalone product or in kits with Merit Angioplasty Packs. It is intended for procedures like balloon angioplasty and stent placement, which restore blood flow through blocked arteries. Merit Medical aims to enhance its leadership in the inflation device market with this new offering.
- Launch of the basixSKY Inflation Device expands Merit Medical's portfolio.
- Device designed for ease of use and efficiency, potentially improving patient care.
- Available as a standalone product and in kits, offering flexibility.
- Expands Merit Medical's presence in the inflation device market.
- No specific financial or clinical performance data provided in the release.
- Potential market adoption and competitive response not addressed.
Versatile analog device offers fast inflation and ease of use, streamlining patient care
SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the basixSKY Inflation Device.
BasixSKY is the latest addition to Merit’s comprehensive inflation device portfolio, which includes both digital and analog devices. The basixSKY is available as a standalone solution and in kits with Merit Angioplasty Packs, configured to offer complementing AccessPLUS™, Honor®, and PhD™ hemostasis valves.
Designed with ease of use in mind, the new device is simple and highly responsive, creating an efficient approach to inflation. Rotational torque and handle revolutions to reach pressure are minimized, and a comfort-grip feature enables one-handed preparation.
Learn more about the basixSKY Inflation Device.
Endovascular interventions, such as balloon angioplasty and stent placement procedures used to widen narrowed or blocked coronary and peripheral arteries, utilize an inflation device. These are minimally invasive techniques that can restore blood flow through diseased vessels and minimize damage to surrounding tissue. In 2024, it is estimated that 1.79 million coronary balloon and stent placement procedures will be performed in the United States.1
“We are pleased to broaden our portfolio of inflation devices,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “With high-quality digital and analog solutions and custom kit options, we remain a leader in the inflation device market. We’re proud of that. We look forward to continuing to serve our healthcare partners, helping them to provide the best patient care.”
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com
1. Clarivate DRG, Market Insights ǀ Interventional Cardiology Devices ǀ United States ǀ 2023, December 29, 2022 (Clarivate, 2022).
FAQ
What is the basixSKY Inflation Device?
When was the basixSKY Inflation Device released?
What procedures use the basixSKY Inflation Device?
What is the stock symbol for Merit Medical?
How does the basixSKY Inflation Device improve patient care?
